These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788 [TBL] [Abstract][Full Text] [Related]
8. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
9. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis. Milecki P; Kwias Z; Martenka DJ Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887 [TBL] [Abstract][Full Text] [Related]
10. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
11. Management of locally advanced prostate cancer: a European consensus. Boccon-Gibod L; Bertaccini A; Bono AV; Dev Sarmah B; Höltl W; Mottet N; Tunn U; Zamboglou N Int J Clin Pract; 2003 Apr; 57(3):187-94. PubMed ID: 12723722 [TBL] [Abstract][Full Text] [Related]
16. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303 [TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for localized carcinoma of the prostate: the role of external beam radiation therapy. Khil MS; Kim JH Henry Ford Hosp Med J; 1992; 40(1-2):103-7. PubMed ID: 1428958 [TBL] [Abstract][Full Text] [Related]
20. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]